378 related articles for article (PubMed ID: 21506127)
1. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
2. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
[TBL] [Abstract][Full Text] [Related]
3. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
5. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
6. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
9. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells.
Kim K; Ryu K; Ko Y; Park C
Br J Haematol; 2005 Oct; 131(1):59-66. PubMed ID: 16173963
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
12. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
13. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
15. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
[TBL] [Abstract][Full Text] [Related]
16. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
[TBL] [Abstract][Full Text] [Related]
17. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
[TBL] [Abstract][Full Text] [Related]
18. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
[TBL] [Abstract][Full Text] [Related]
19. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
20. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines.
Mukhopadhyay A; Bueso-Ramos C; Chatterjee D; Pantazis P; Aggarwal BB
Oncogene; 2001 Nov; 20(52):7597-609. PubMed ID: 11753638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
